Skip to main content
SpringerLink
Log in

Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA) in cancer patients

  • Original Articles
  • CBDCA Blood Clearance
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The blood and urinary clearances of cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA, JM8) were determined in four patients with malignancy. A 40 μCi iv injection of 191Pt/193Pt (3:1)-labelled CBDCA was followed by serial blood and urine sampling to 72h.

The blood clearance was triphasic, mean values for the fast, intermediate, and slow phases being 10.8 min, 2.5 h, and 125 h, respectively. The fraction of activity excreted in the urine within the first 6 h had a mean value of 66.7%, contrasting with 26.4% for cisplatin. There was only a small fraction of CBDCA excreted by the slow phase (1.5%) as against an average of 20% for CHIP and 27% for cisplatin.

The early and rapid renal clearance of CBDCA may account for reduced nephrotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bruno S, Poster DS, Higby DJ, Burke P, Mittelman A (1980) Parameters of nephrotoxicity in relation to the administration of cis-DDP. Proc Am Assoc Cancer Res 21:150

    Google Scholar 

  2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR, Cobley T (1982) Early clinical studies with cis-diammine 1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140

    Google Scholar 

  3. Durant JR (1980) CisPlatin: A clinical overview. In: Prestayko AW, Crooke ST, Carter SK (eds) Cis-Platin: Current status and new developments. Academic Press, New York London Toronto Sydney San Francisco, pp 317–321

    Google Scholar 

  4. Harrap KR, Jones M, Wilkinson CR, Clink HMcD, Sparrow S, Mitchley BCV, Clake S, Veasey A (1980) Antitumour, toxic and biochemical properties of cisplantin and eight other platinum complexes. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: Current status and new developments. Academic Press, New York London Toronto Sydney San Francisco, pp 193–212

    Google Scholar 

  5. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, Schwartz MK, Young CW, Reidenberg MM (1980) Comparison of methods of evaluating nephrotoxicity of cisplatinum. Clin Pharmacol Ther 27:557

    Google Scholar 

  6. Nadler SB, Hidalgo JU, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51:224–232

    Google Scholar 

  7. Siddik ZH, Newell R, Jones M, Boxall FE (1982) Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) (CBDCA JM8) in mice and rats. Proc Am Assoc Cancer Res 23:168

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biophysics, University of Manchester, Medical School, Manchester

    H. Sharma & A. Smith

  2. Cancer Research Campaign Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester

    N. Thatcher & D. Crowther

  3. Department of Chemistry, University of Manchester, Institute of Science and Technology, Manchester

    J. Baer, A. Zaki & C. A. McAucliffe

  4. Regional Department of Medical Physics and Bioengineering, Christie Hospital and Holt Radium Institute, Manchester

    S. Owens

  5. Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester, England

    B. W. Fox

Authors
  1. H. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Thatcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Baer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Zaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. A. McAucliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Crowther
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Owens
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B. W. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, H., Thatcher, N., Baer, J. et al. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA) in cancer patients. Cancer Chemother. Pharmacol. 11, 5–7 (1983). https://doi.org/10.1007/BF00257407

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257407

Keywords

Search

Navigation